|
Total Patients
|
761
|
|
Baseline Clinical Characteristics
| |
|
Charlson Comorbidity Index*
|
1.1 (± 1.6)
|
| |
1 [0 - 12]
|
|
Osteoporosis Drug Utilization in Pre-Period n,(%)
|
353 (46.4%)
|
|
Bisphosphonate n,(%)
|
283 (80.2%)
|
|
Calcitonin n,(%)
|
39 (11.0%)
|
|
Selective Estrogen Receptor Modulator (SERM) n,(%)
|
42 (11.9%)
|
|
Conjugated Estrogen n,(%)
|
22 (6.2%)
|
|
Fracture in the 6 Month Pre-Period n, (%)
|
386 (50.7%)
|
|
Fracture in the 12 Month Pre-Period n,(%) **
|
443 (58.2%)
|
|
Comorbidity (Top 10 Identified) n, (%)†
| |
|
Other disorders of bone and cartilage (733.)
|
752 (98.8%)
|
|
Essential hypertension (401.)
|
546 (71.7%)
|
|
Disorders of lipid metabolism (272.)
|
529 (69.5%)
|
|
General symptoms (780.)
|
474 (62.3%)
|
|
Other and unspecified disorders of back (724.)
|
402 (52.8%)
|
|
Symptoms involving respiratory system and other chest symptoms (786.)
|
391 (51.4%)
|
|
Other and unspecified disorders of joint (719.)
|
382 (50.2%)
|
|
Osteoarthritis and allied disorders (715.)
|
361 (47.44%)
|
|
Other disorders of soft tissues (729.)
|
333 (43.8%)
|
|
Cataract (366.)
|
281 (36.9%)
|
|
Post-Period Clinical Characteristics
| |
|
Fracture in the 12 Month Post-Period n,(%)
|
222 (29.2%)
|
|
Time Between Index Date and First Fracture (Days)*
|
200 (± 81)
|
| |
181 [91 - 364]
|
|
Proportion of Days Covered (PDC) Between Index Date and First Fracture*
|
0.46 (± 0.3)
|
| |
0.38 [0.08 - 1.0]
|
|
Reached Part D Coverage Gap During 12 Month Follow-up Period n, (%)
|
586 (77%)
|
|
Out of Pocket Cost for All Prescription Claims During 12 Month Follow-up
|
$2,082 (± $2,189)
|
|
Period*
|
$991 [$30 - $10,894]
|
|
Out of Pocket Cost for Teriparatide Prescription Claims During 12 Month
|
$1,247 (± $1,832)
|
|
Follow-up Period*
|
$228 [$15 - $7,165]
|
